# Dose Escalation and Expansion Study of SYH2043 in Patients With Advanced Malignant Tumors

> **NCT05728541** · PHASE1 · UNKNOWN · sponsor: **CSPC Ouyi Pharmaceutical Co., Ltd.** · enrollment: 367 (estimated)

## Conditions studied

- Advanced Malignant Tumors

## Interventions

- **DRUG:** SYH2043

## Key facts

- **NCT ID:** NCT05728541
- **Lead sponsor:** CSPC Ouyi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-01
- **Primary completion:** 2026-02-01
- **Final completion:** 2026-03-01
- **Target enrollment:** 367 (ESTIMATED)
- **Last updated:** 2023-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05728541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05728541, "Dose Escalation and Expansion Study of SYH2043 in Patients With Advanced Malignant Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05728541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*